NHS boss Amanda Pritchard steps down from her role
NHS England chief executive Amanda Pritchard will leave her role at the end of March, it has been announced.
Ms Pritchard – who has come in for criticism from MPs in recent months – said it had been 'an enormous privilege to lead the NHS in England through what has undoubtedly been the most difficult period in its history'.
NHS England said that, having discussed everything with Health Secretary Wes Streeting in recent months – and now that the NHS has 'turned a corner' – Ms Pritchard had 'decided now is the right time to stand down'.
Sir James Mackey, who is the national director of elective recovery for the health service, will be taking over as interim NHS chief executive.
Ms Pritchard has come under intense scrutiny, with MPs on the Health and Social Care Committee saying earlier this month they were disappointed and frustrated by the 'lengthy and diffuse answers' she and other officials gave them under questioning.
Last week, she admitted 'we're not all brilliant performers at committee hearings' as she was challenged on the issue.
Speaking to BBC Breakfast, Ms Pritchard was asked whether she was the right person to lead the health service.
Ms Pritchard said: 'We are far from complacent. I mean, particularly they were talking to us about productivity, and spending public money wisely is an absolute priority for us…
'Equally, I think I'll be honest enough to say we're not all brilliant performers at committee hearings, but it's absolutely right that we are scrutinised by Parliament.'
MPs on the Public Accounts Committee have also accused her and officials at the Department of Health and Social Care of being 'complacent' and lacking dynamism.
Ms Pritchard became head of the health service in 2021 – the first time the post has been held by a woman – after previously being its chief operating officer.
She began her NHS career as a graduate management trainee in 1997 after studying at Oxford University and has held a variety of other NHS management positions.
Before joining NHS England in 2019, she served as chief executive of Guy's and St Thomas' NHS Foundation Trust in London.
She was also deputy chief executive at Chelsea and Westminster NHS Foundation Trust.
Ms Pritchard, who is married with three children, studied modern history at St Anne's College, Oxford.
In a statement on Tuesday, she said: 'I am immensely proud of the NHS response to Covid-19, and how we have delivered steady recovery from the inevitable impacts of the pandemic – with performance in urgent and emergency care, elective and cancer all improving over the past two years, while NHS teams delivered record levels of activity in primary care, community and mental health services, meaning millions more appointments for patients.
'We always knew the recovery period after a once-in-a-century pandemic was going to be incredibly challenging, and whilst the timeliness and experience of care is still not good enough for too many people, the NHS has achieved a great deal in the face of historic pressure thanks to a relentless focus on innovation and reform.'
She added: 'While it has been a hugely difficult decision for me to stand down, I believe now is the right time – with the NHS making continued progress in our recovery, and with the foundations firmly in place to deliver the 10 Year Health Plan.
'The NHS is full of extraordinary people, who do extraordinary things every day for patients.
'The achievements I have listed above, and many more, are theirs – and I am confident they will continue to achieve incredible things for patients now, and into the future.'
Mr Streeting said: 'Amanda can be enormously proud of the leadership she has given in the face of the biggest health emergency for our country in modern history, as well as steering NHS England during turbulent political waters and six secretaries of state in her time as chief executive. She has led with integrity and unwavering commitment.
'The start of the next financial year and the publication of the 10 Year Plan for Health will be pivotal moments on the road to reform.
'We will also require a new relationship between the Department for Health and Social Care and NHS England.'
The interim chief executive of NHS Providers, Saffron Cordery, said: 'Amanda has been an inspirational leader.
'She has embodied the values of the NHS, acting on her genuine passion to ensure high quality care for NHS patients.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Time to face the harsh realities of spending orthodoxy
Labour came to power fatuously parroting the word 'change' and yet has shown itself to be the same old tax and spending party it has always been. What it meant was a change of party in office not a change of direction. Not only have taxes gone up but so-called protected spending is set to rise despite record debt levels. Yet if ever a public policy has been tested to destruction surely it is the notion that the NHS will improve if only more money is thrown at it. Even Sir Keir Starmer and Wes Streeting, the Health Secretary, are on record as saying that higher health spending is not the answer to the endemic flaws in the health service and yet another £30 billion is to be announced for the next three years on top of the £22 billion handed over after last year's general election, much of which went on pay and showed nothing in the way of productivity improvement. No mainstream politician is prepared to acknowledge that the problem with the NHS is the fact it is a nationalised industry with all the inherent inefficiencies associated with such. Most other advanced economies in Europe and elsewhere have social insurance systems which work better. But the insistence in Britain of cleaving to the 1948 'founding principle' that treatment should be free at the point of delivery has become a quasi-religious doctrine that few dare challenge. Only Nigel Farage has questioned the wisdom of continuing with a system that patently fails to achieve what others manage to do but has been noticeably quiet on the subject recently because Labour will exploit it mercilessly to see off the Reform people that they will have to pay for something they have always had for free is even more difficult when political parties are prepared to see the health system get worse rather than reform it. The same is true of welfare. Taking benefits from people, even when they are payments introduced just a few years ago like the winter fuel allowance, is hard if the reasons are not explained and the issue is 'weaponised' by opponents. Yet unless the welfare budget is brought under control it will bankrupt the country. If change is to mean anything then we need politicians finally to understand the extent of the country's difficulties and make decisions accordingly. Will we see that from the Chancellor on Wednesday? Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Yahoo
5 hours ago
- Yahoo
ADHD drugs back in the spotlight after study debunks rising prevalence
An increasing number of patients are seeking support for attention-deficit/hyperactivity disorder (ADHD), with pharmacological-based treatments an important part of medical care for the neurodevelopmental condition. A study published this week in the Journal of Affective Disorders has found that greater awareness and acceptance around the disorder has led to more people seeking help. The research, led by a team at King's College, London, debunks claims that the disorder is 'naturally' on the rise. The data comes as a national taskforce in England investigates what this rising demand for support means for the NHS. Figures published in May 2025 by NHS England estimated there were nearly 2.5 million people in England with ADHD. This includes more than 550,000 currently waiting for an assessment. Every month 20,000 more people are referred for support, a rise of 13% compared to last year. Pharmaceutical Technology looks at some of the current options in the UK and casts an eye ahead to what the future drug landscape might contain. The first choice for patients with ADHD is methylphenidate, which belongs to a class of drugs called central nervous system (CNS) stimulants. The drug, which works by blocking the reuptake of norepinephrine and dopamine, increases activity in the brain, including regions associated with attention and behaviour. It is known under the brand names Ritalin, manufactured by Novartis, and Johnson and Johnson's Concerta. There is also Equasym and Xenidate, among others. Lisdexamfetamine dimesylate is also used to treat patients with ADHD. Like methylphenidate, lisdexamfetamine is a CNS stimulant and acts as a norepinephrine and dopamine reuptake inhibitor (NDRI). This drug is known under the brand name, among others, as Elvanse and Vyvanse, both manufactured by Takeda. While stimulants are fast acting, with side effects felt soon after administration, non-stimulant drugs take longer, yet can offer an alternative if drugs like methylphenidate and lisdexamfetamine dimesylate do not work. While improving, access to pharmacological-based treatments is still impaired amid an ongoing global shortage that began in September 2023. Methylphenidate and lisdexamfetamine were primarily affected – the shortage arising due to a combination of manufacturing issues and increased global demand. A separate study published in The American Journal of Managed Care in March suggested that overdiagnosis of ADHD is fuelling the shortage of stimulation medications. One of the most advanced candidate drugs, and one with notable buzz surrounding it, is Axsome's Sunosi (solriamfetol). Sunosi, which is also an NDRI but not a conventional stimulant, met its primary endpoint in a Phase III trial (NCT05972044) earlier this year. The medication led to a 45% drop in ADHD symptoms. As measured by the Adult ADHD Investigator Symptom Rating Scale (AISRS), 150mg Sunosi dosed achieved average reductions from baseline of 17.7 points, compared to 14.3 points for placebo. Sunosi is already approved in the UK to treat excessive daytime sleepiness (EDS) in adults with narcolepsy, with or without cataplexy. Certain patients with obstructive sleep apnoea (OSA) are also eligible to take the medication. In 2022, Axsome paid $53m up front to acquire Sunosi from Jazz Pharmaceuticals. A drug with a recent approval extension in the US, though not the UK, was Supernus Pharmaceuticals' Qelbree (viloxazine extended-release capsules). The mechanism of action of Qelbree, though unclear, is thought to be through inhibiting the reuptake of norepinephrine. Originally approved for children in 2021, the FDA updated the drug's label in January this year to include adults. ADHD treatments were in the political crosshairs in the US recently. The disorder, along with autism, was singled out by the Trump administration for an 'over-utilisation of medication'. Pharmaceutical intervention remains a helpful part of managing the disorder, though it is part of a combination of treatments that also include coaching and lifestyle changes. "ADHD drugs back in the spotlight after study debunks rising prevalence" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Mobile clinics aim to boost rural health care measles vaccinations amid outbreak
The "Wellness on Wheels" program launched in spring of 2024. (Courtesy of South Dakota Department of Health) The South Dakota Department of Health plans to send its fledgling mobile clinics to underserved and undervaccinated areas of the state in response to the nationwide measles outbreak making its way to the state. Last year, South Dakota reported its first measles case in nine years. The state Department of Health recently reported the state's first case this year in Meade County in western South Dakota. Last week, on Friday, a second case was reported in Rapid City. People who visited Sam's Club in that city on June 1, or Dakota Premier Medical Center the following day were urged by the department to monitor themselves for symptoms for 21 days. Measles is a highly contagious viral disease that spreads through the air. Those who lack immunity from vaccination or past infection are highly likely to catch it from an infected person. As surrounding states report more cases, Health Department Secretary Melissa Magstadt said the state's 'Wellness on Wheels' clinics can help encourage vaccinations. 'I question it myself': South Dakota vaccination rates fall amid mistrust and misinformation The fleet boasts five vehicles equipped to provide immunizations, test for sexually transmitted diseases such as syphilis, as well as provide screenings, prenatal care and other support. The effort fills in gaps to public health care access across the state, especially in rural and tribal communities, Magstadt said. 'It's about how we can actively use these tools to reach underserved populations,' Magstadt said. 'It's not something I would have thought about looking to leverage for something like measles vaccinations before.' The department hasn't decided where to send their fleet. Counties with the fewest kindergarteners vaccinated per capita for measles, mumps and rubella include Faulk, Jones and Hutchinson, state data shows. South Dakota counties that share tribal land and rural counties in south-central areas of the state rank the worst for clinical care use and access in the state, according to the University of Wisconsin Population Health Institute's 2023 report. Federal COVID relief funds paid for Wellness on Wheels. 'Because of the pandemic, public health infrastructure was found to be wanting,' Magstadt said. That infrastructure missed 'critical pieces' that hadn't been invested in, she said, such as health care access in rural areas. More than a hundred rural hospitals in the U.S. have closed in the last decade. The program, launched in April of last year, cost about $800,000 in federal funding. The state's public health COVID funding was also used to support a community health worker program, update emergency medical service equipment and telemedicine access, analyze the state of emergency medical services in South Dakota, and build a Public Health Lab and department training center. Magstadt said staff working with the Women, Infants and Children (WIC) program requested the mobile units. WIC is a federal-state program that provides healthy food, nutrition education and health care referrals to low-income women and their young children. So far, Wellness on Wheels staff have mainly driven to events. Magstadt said the department has focused on increasing awareness of the program and building trust in communities and among tribal leaders. She plans to have staff drive the buses to rural communities more regularly to increase exposure and encourage use. 'Being consistently at a facility or place every other week will help people find it,' Magstadt said. 'We talk about the importance of STI testing, for example, but if you don't know where to get tested then that's another barrier.' Magstadt plans to have the department park one of the vehicles at a homeless shelter in Rapid City this summer as well to encourage underserved urban communities to seek services. 'We like people to be connected to primary care services, but there are unique situations where it's harder to get to health care facilities,' Magstadt said. She compared the mobile clinics as a return to home visits by doctors. That practice largely ceased in the 1960s due to cost efficiencies. 'It's a part of this menu of health care access and options no longer requiring people to come to a clinic or health care system,' Magstadt said, 'but health care being taken to patients and families who need it.' Mobile health care clinics are available in every state. They range from public entities like South Dakota's Wellness on Wheels, to specialized, private care. Other mobile clinics operating in South Dakota, according to Mobile Health Map, include: Delta Dental Mobile Program Horizon Health on Wheels Midwest Street Medicine Mobile Women's Health Unit VA Mobile Counseling Program
